# Evaluate Measurement Instruments Relevance in Assessing Effectiveness of ACARIZAX® in House Dust Mite Allergic Rhinitis

> **NCT06151938** · — · UNKNOWN · sponsor: **ALK-Abelló A/S** · enrollment: 100 (estimated)

## Conditions studied

- Allergic Rhinitis Due to House Dust Mite
- Allergic Asthma

## Interventions

- **DRUG:** Standardised allergen extract from house dust mites

## Key facts

- **NCT ID:** NCT06151938
- **Lead sponsor:** ALK-Abelló A/S
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-11-21
- **Primary completion:** 2025-05-20
- **Final completion:** 2025-08-20
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06151938

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06151938, "Evaluate Measurement Instruments Relevance in Assessing Effectiveness of ACARIZAX® in House Dust Mite Allergic Rhinitis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06151938. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*